NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on transforming the surgical diagnosis and treatment of neurological disorders, announced today that it will release financial results for its fiscal second quarter ended March 31, 2026, before market open on Tuesday, May 12, 2026. Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on the same day to discuss the results, provide a corporate update, and answer questions from telephone participants.
The conference call details are as follows: participants can dial 888-506-0062 (toll-free within the U.S.) or 973-528-0011 (international) and use participant access code 224785. A live webcast will also be available at this link. Participants are encouraged to join at least five minutes before the start of the call to ensure timely participation. A replay of the call will be accessible through Tuesday, May 26, 2026, by calling 877-481-4010 (U.S.) or 919-882-2331 (international) and using replay passcode 53948. The webcast replay will remain available through Wednesday, May 12, 2027.
NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by providing diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
The upcoming financial results and corporate update will provide investors and stakeholders with insights into the company's performance and progress in advancing its technology platform. For more information about NeuroOne, visit nmtc1.com. The company's focus on improving surgical care options for patients with neurological disorders positions it as a key player in the medical technology space, and the earnings call is expected to shed light on recent developments and future directions.
